COUR Pharma

📍 Skokie, United States🗓 Founded 2015👥 78 employees💰 Last funded Sep 2025
Pharmaceutical Manufacturing🌐 courpharma.com
Website LinkedIn
COUR is a clinical-stage biotechnology company working to reprogram the immune system to restore health in people suffering from autoimmune diseases. Using our proprietary COUR nanoparticle (CNP) platform for antigen-specific immune tolerance, we develop first-in-class disease-modifying therapies that target disease at its root—without suppressing normal immune system function. With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in COUR Pharma?
COUR Pharma has 2 investors on record on gritt.io and 2 late-stage investors.
When did COUR Pharma last raise funding?
The most recent investment in COUR Pharma recorded on gritt.io was in September 2025.
When was COUR Pharma founded?
COUR Pharma was founded in 2015.
What industry is COUR Pharma in?
COUR Pharma operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is COUR Pharma based?
COUR Pharma is headquartered in Skokie, United States.